Table 2.
Evidence about the role of CB2 receptors in AD obtained from genetically modified mice.
| References | Animal model | AD-related characteristics |
|---|---|---|
| Chen et al., 2012 | 5xFAD/CB2(−/−) | = Effect of a MAGL inhibitor on reducing astrocytes |
| Around plaques | ||
| Koppel et al., 2014 | J20 APP/CB2(−/−) | ↑ Soluble Aβ1−42 |
| ↑ Plaque deposition | ||
| ↓ Total tau | ||
| ↑ Microglia associated to plaques | ||
| Schmöle et al., 2015 | APP/PS1/CB2(−/−) | = Cognitive performance |
| = Plaque deposition | ||
| ↓ Concentrations of soluble Aβ1−40and Aβ1−42 | ||
| ↓ Microglial cells and infiltrated macrophages | ||
| ↓ Levels of pro-inflammatory chemokines and cytokines | ||
| Aso et al., 2016 | APP/PS1/CB2(−/−) | = Cognitive performance |
| = Cognitive improvement induced by Δ9-THC+CBD | ||
| ↑ Soluble Aβ1−40 | ||
| ↑ Plaque deposition | ||
| = Tau phosphorylation around plaques | ||
| ↓ Effect of Δ9-THC+CBD on reducing microglia around plaques |